Last reviewed · How we verify
NCT05408702: MYaEX
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
trial in Autoimmune Myasthenia Gravis in 500 participants. Completed in 15 May 2022.
15 May 2022
Quick facts
| Lead sponsor | Institut de Myologie, France |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 12 November 2021 |
| Primary completion | 15 May 2022 |
| Estimated completion | 15 May 2022 |
| Sites | 1 location across France |
Conditions studied
- Autoimmune Myasthenia Gravis — all drugs for Autoimmune Myasthenia Gravis →
- Lambert-Eaton Myasthenic Syndrome — all drugs for Lambert-Eaton Myasthenic Syndrome →
- Congenital Myasthenic Syndrome — all drugs for Congenital Myasthenic Syndrome →
- Myasthenia Gravis — all drugs for Myasthenia Gravis →
Sponsor
Institut de Myologie, France — full company profile →
Who can join
18 and older, any sex, with Autoimmune Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A few recent observational studies show that despite the lack of clear recommendations, many individuals with myasthenia participate in exercise. However, no link has been found between exercise and the severity of myasthenia symptoms, measured by the Muscle Myasthenia Score or the Myasthenia Gravis Composite Score. This suggests that there are other factors that may limit or prevent some individuals from being active, or factors which may facilitate participation in exercise. Studies in other diseases have shown that there are internal (beliefs, motivation, etc.) and external (cost, accessibility, etc.) factors unrelated to the disease which may play a role in exercise participation. The aim of this study is to identify factors that facilitate or limit exercise in individuals with autoimmune myasthenia gravis, congenital myasthenia syndrome and Lambert-Eaton syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05408702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut de Myologie, France trials
Trials by the same sponsor.
- NCT07321977 — Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular D · NA · recruiting
- NCT07321990 — Study of the Reproducibility of the French Version of the Modified SMAFRS Scale · recruiting
- NCT06354790 — Natural History Study of Children With LAMA2-related Dystrophies · recruiting
- NCT05839145 — Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study · NA · unknown
- NCT05798325 — Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient Mobility in Daily Li · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05408702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Myologie, France
- Last refreshed: 7 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05408702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing